Genmab A/S (GMAB), a Danish biotechnology company's subsidiary, Genmab Holding II B.V., announced on Friday that the conditions to its tender offer to acquire all Merus N.V. (MRUS) shares for $97 in cash have been met.
The deal supports the company's plan to move toward a fully owned model and strengthens its pipeline by adding Merus' lead asset, petosemtamab. Genmab expects to launch petosemtamab in 2027, and sees at least $1 billion in yearly sales potential by 2029.
At the offer deadline of 5:00 p.m. New York time on December 11, a total of 71,463,077 Merus shares, 94.2% of the outstanding shares, had been tendered.
A subsequent offering period of ten business days begins December 12 and runs until 5:00 p.m. New York time on December 29.
During this period, the company will purchase additional Merus shares at the same $97 per share price, less any required taxes, with immediate acceptance and quick payment.
After the subsequent offering period, the company plans to acquire the remaining Merus shares through previously disclosed follow-on steps, with shareholders receiving payment afterward.
Genmab closed the regular trading session on December 12, 2025, at $32.30, higher $1.06 or 3.39%. Later, in overnight trading, the share price rose to $33.30, gaining $1 or 3.10%, as of 11:00 PM EST.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.